Connect with us

Press Release

UniArt’s impossible art formula gallery bring bottom-up NFT appreciation with vote mining on 30th Sep

Published

on

Preamble

Recently, “Loot” has been spreading virally throughout the crypto community. Industry key opinion leaders (KOLs), founders of quality projects, and investment institutions all pay close attention to the emerging “bottom-up” concept, and more community members are excited about it.

Despite the term bottom-up only recently coming into the limelight, in essence, the philosophy may be at the root of the entire crypto economy. Bitcoin, for example, breaks the rules of centralized government-issued fiat currency by enabling anyone that follows its PoW consensus algorithm to produce a new currency. On the other hand, Ether allows developers to build arbitrary dApps on top of it without permission, and its prosperity hinges on the frequency of this.

These two patriarchs of the crypto economy have opened up a bottom-up path outside the centralized internet. The bottom here can be anyone. The top is no longer governments or corporations but now code, algorithms, data, and consensus mechanisms. Loot is the first bottom-up non-fungible token (NFT), possessing similar intrinsic characteristics at the root of its explosion.

The most widespread application of NFT is currently in the art sector. Crypto community practitioners are working to bring NFT into the traditional art marketplace. To accomplish this, NFT must have general acceptance and market consensus, not just within a niche group of artists and appreciators. Take the most common financial application of collateralized lending, for example; a starving artist, globally unknown pledges his minted NFT to you, the potential lender. They claim it is worth US$10,000 and want to borrow against this collateralized value. Naturally, you are hesitant, unsure of its market value, and even if a current buyer is willing to purchase it at that price, you are still uncertain about its future value. In short, there is not enough market consensus for that NFT. However, let’s use CryptoPunk or BAYC as collateral in this example. Results would be the opposite because each of these digital assets already has widespread market consensus, having been classified as antiques in the NFT community. Therefore, the fair market valuation of NFT is critical to achieving market consensus in the financial sector. Exploring a suitable value solution for NFT is beneficial in a financial application, which opens up various other possibilities for NFT, leading to the further development of the whole crypto community.

UniArts aims to uncover NFT fair market valuation through its customized bottom-up Nominated Proof-of-Stake (NPoS) economic model, aspiring decentralized incubation of creators and their works. In this paper, the core concept of UniArts will be comprehensively explained using this bottom-up concept as the source idea.

Bottom-up NFT Fair Market Valuation

The term bottom-up can be understood differently in different contexts; building on top of a foundation is not a required characteristic. In the context of UniArts, bottom (in a non-pejorative sense) can be understood as what people define together and top as the fair value of NFT. This bottom-up approach is contrasted with more traditional top-down valuation, which was determined mainly by centralized auction houses or prominent collectors. Less renowned artists rarely gained any attention, and in the rare chance they did, their work would often be considered nearly worthless. Such an approach does nothing to showcase potentially exceptional pieces for the mere reason they are unknown, and they remain misunderstood by the public.

In the UniArts network, $UART holders are deemed “nominators,” pledging their tokens as “votes” for an NFT they admire. The more votes an NFT receives, the more people approve of it, and the higher the consensus level. When people are required to invest in their decisions, they become much more selective. Since there is value in $UART, the votes that an NFT receives indicate its fair market value. In the early stages of UniArts’ development, the small user base may not be sufficient to tie the word fair to an NFTs value, but as the network expands, it will become more and more convincing. This process can be referred to as the “flywheel effect.”

Appreciate to Earn

“Appreciate To Earn” is a new concept and a subset of “Play To Earn,” in that merely appreciating an NFT is akin to the process of playing. Axie Infinity, a chain game that has been popular in the crypto community for a while now, relied on this “Play To Earn” concept as the fuel to expand its user base. From this vetted example, we know that it is a viable business model.

UniArt’s Nominators pledge $UART and select an NFT they appreciate to earn more $UART, including a base pledge bonus and a block bonus for top-ranked NFTs. In this process, the word appreciate corresponds to the nominator, and the word earn corresponds to the earned $UART. In Axie Infinity, players buy a pet “Axie” as an entry ticket to the game and earn revenue in-game from this Axie. In UniArts, $UART is the entry ticket into the network.

Play to Earn can be viewed as a modern concept to attract new users. Traditional game companies pay third-party advertising companies to attract new users, but these users do not receive any income. Blockchain games use tokens to incentivize new users, which is a disguised way of attracting traffic; an alternative form of advertising, where the fees paid to advertising companies are instead attributed to the user. If this alternative form of advertising is integrated into a chain game’s economic model, one can only expect explosive organic user growth. Similarly, the Appreciate to Earn concept will cause natural growth of UniArt’s user base, eventually to the point where fair valuation is achieved.  

Multi-Chain NFT Gallery “Impossible Art Formula”

UniArts is native to Polkadot, and one of its strategic plans is to spread the NFT gallery to more popular blockchains, the first stop being Polygon. Mechanically, the gallery will be similar to the NPoS economic model but not identical.

  • Six NFTs will be presented in each issuance, and users can pledge $UART or $WETH to vote on their favorite NFT.
  • There are a total of 3 revenue pools, including a casting pool, a general pool, and a bonus pool. The bonus pool added to the gallery is unique in comparison to the NPoS model mentioned above. The casting pool is a pool in which $UART is minted into an NFT based on the percentage of votes received by the NFT. The general pool allocates rewards based on the proportion of user votes to the total number of votes in the corresponding NFT.
  • At the end of each voting period, NFT owners have the option to participate in the next three-day auction. The bonus pool is allocated to the corresponding NFT according to the ratio of the price sold in the auction to the sum of all prices traded in the auction for that period. This pool is then allocated to users that voted in the general pool, as mentioned in (2).
  • Specific details can be found in the following chart:

UARTs tokens are capped at 200 million, with 10% held by the team and released after 3 years, 12% by early stage investors, 10% by the treasury, and the rest by NFT vote mining, “Appreciate To Earn”.

“Impossible Art Formula” demonstrates the lack of a perfect solution in art valuation as everyone has their unique preferences. Let’s solve this by using $UART to appoint the “Hamlet” we fancy.

Concluding Remarks

UniArts has customized the NPoS economic model for NFT with an Appreciate To Earn mechanism based on the bottom-up source concept, which helps NFT discover its fair value. This value discovery fills an essential gap in applying NFT to traditional art and financial systems, paving a new path in crypto circles.

The impossible art formula is accessible now and will be online on 30th Sep.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Published

on

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.

AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.

The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“

Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.

“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“

The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.

Media Contact

Company: AI Labs

Contact: Media Team

Email: ryan@academic-labs.org

Website: https://ai-labs.live/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

Published

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.

 

The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.

 

The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.

 

Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.

 

Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.

 

Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.

 

More Information About Povorcitinib Phosphate Tablets

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.

 

A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).

 

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

 

Reference

1、China Insights Consultancy (CIC) report

2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

Published

on

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST